Bacterial vaginosis and vulvovaginal candidiasis
Objective. To carry out a systems analysis of the data available in the current literature on the pathogenesis, therapy, and prevention of vaginal infections caused by the pathogens of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC).Kuznetsova I.V., Chilova R.A.
Material and methods. The review includes the data of foreign and Russian articles published in the past 10 years and found in Pubmed on this topic.
Results. The paper highlights the main pathways of pathogenesis and the causes of recurrent vaginal coinfection. It describes methods for the treatment of women with BV and VVC and presents the optimal therapy and prevention schemes for recurrent vaginal infectious diseases, which have evidence-based effectiveness.
Conclusion. The features of a microbial portrait and immune status predispose to recurrent BV and VVC, the presence of which results in coinfection. The cause of the latter is also repeated therapy for recurrent monoinfection. First-line therapy for BV is recognized to include metronidazole and clindamycin; the advantages of the latter are a wider spectrum of activity against the microorganisms that are difficult to identify. To treat coinfection and to prevent VVC in patients with BV, it is advisable to use fluconazole that also remains a first-line treatment option for vaginal infection caused by Candida albicans.
Keywords
bacterial vaginosis
vaginitis
vulvovaginal candidiasis
recurrent vulvovaginal candidiasis
fluconazole
clindamycin
pathogenesis
treatment
prevention
References
1. Sherrard J., Donders G., Lead D.W. European (IUSTI/WHO) guideline on the management of vaginal discharge, 2011.
2. Ling Z., Kong J., Liu F., Zhu H., Chen X., Wang Y. et al. Molecular analysis of the diversity of vaginal microbiota associated with bacterial vaginosis. BMC Genomics. 2010; 11: 488.
3. Frobenius W., Bogdan C. Diagnostic value of vaginal discharge, wet mount and vaginal pH – an update on the basics of gynecologic infectiology. Geburtshilfe Frauenheilkd. 2015; 75(4): 355-66.
4. Workowski K.A., Bolan G.A.; Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm. Rep. 2015; 64(RR-03): 1-137.
5. Goldenberg R.L., Culhane J.F., Iams J.D. Epidemiology and causes of preterm birth. Lancet. 2008; 371(9606): 75-84.
6. Martin Lopez J.E. Candidiasis (vulvovaginal). BMJ Clin. Evid. 2015; 2015: pii: 0815.
7. Mitchell C., Marrazzo J. Bacterial vaginosis and the cervicovaginal immune response. Am. J. Reprod. Immunol. 2014; 71(6): 555-63.
8. Sirota I., Zarek S.M., Segars J.H. Potential influence of the microbiome on infertility and assisted reproductive technology. Semin. Reprod. Med. 2014; 32(1): 35-42.
9. Lamont R.F., Sobel J.D., Akins R.A., Hassan S.S., Chaiworapongsa T., Kusanovic J.P., Romero R. The vaginal microbiome: new information about genital tract flora using molecular based techniques. BJOG. 2011;118(5): 533-49.
10. Атрошкина М.Е., Ильина Е.Н., Плахова К.И. Разработка ДНК-биочипа для исследования микробных сообществ. Молекулярная медицина. 2009; 3: 23-31. [Atroshkina M.E., Ilyina E.N., Plakhova K.I. Development of DNA-biochip for the study of microbial communities. Molekulyarnaya meditsina. 2009; 3: 23-31. (in Russian)]
11. Прилепская В.Н., Мирзабалаева А.К., Кира Е.Ф., Гомберг М.А., Аполихина И.А., Байрамова Г.Р. Федеральные клинические рекомендации. Диагностика и лечение заболеваний, сопровождающихся патологическими выделениями и половых путей женщин. М.: Российское общество акушеров-гинекологов; 2013. [Prilepskaya V.N., Mirzabalaeva A.K., Kira E.F., Gomberg M.A., Apolikhina I.A., Bayramova G.R. Federal clinical guidelines. Diagnosis and treatment of diseases accompanied by pathological secretions and the genital tract of women. Moscow: Russian Society of Obstetricians and Gynecologists; 2013. (in Russian)]
12. Rathod S.D., Buffler P.A. Highly-cited estimates of the cumulative incidence and recurrence of vulvovaginal candidiasis are inadequately documented. BMC Womens Health. 2014; 14: 43.
13. Achkar J.M., Fries B.C. Candida infections of the genitourinary tract. Clin. Microbiol. Rev. 2010; 23(2): 253-73.
14. Ilkit M., Guzel A.B. The epidemiology, pathogenesis, and diagnosis of vulvovaginal candidosis: a mycological perspective. Crit. Rev. Microbiol. 2011; 37(3): 250-61.
15. Foxman B., Muraglia R., Dietz J.P., Sobel J.D., Wagner J. Prevalence of reccurent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J. Low. Genit. Tract. Dis. 2013; 17(3): 340-5.
16. Swidsinski A., Mendling W., Loening-Baucke V., Swidsinski S., Dörffel Y., Scholze J. et al. An adherent Gardnerella vaginalis biofilm persists on the vaginal epithelium after standard therapy with oral metronidazole. Am. J. Obstet. Gynecol. 2008; 198(1): 97. e1-6.
17. Naglik J.R., Moyes D. Epithelial cell innate response to Candida albicans. Adv. Dent. Res. 2011; 23(1): 50-5.
18. Salusto F., Zielinski C.E., Lanzavecchia A. Human Th17 subset. Eur. J. Immunol. 2012; 42(9): 2215-20.
19. Wuthrich M., Deepe G.S., Klein B. Adaptive immunity to fungi. Annu. Rev. Immunol. 2012; 30: 115-48.
20. Borges S., Silva J., Teixiera P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch. Gynecol. Obstet. 2014; 289(3): 479-89.
21. Foster L.M., Tompkins T.A., Dahl W.J. A comprehensive post-market review of studies on a probiotic product containing Lactobacillus helveticus R0052 and Lactobacillus rhamnosus R0011. Benef. Microbes. 2011; 2(4): 319-34.
22. Ma B., Forney L.J., Ravel J. Vaginal microbiome: rethinking health and disease. Annu. Rev. Microbiol. 2012; 66: 371-89.
23. Copinath S., Iwasaki A. Cervicovaginal microbiota: simple is better. Immunity. 2015; 42(5): 790-1.
24. McClelland R.S., Richardson B.A., Hassan W.M., Graham S.M., Kiarie J., Baeten J.M. et al. Prospective study of vaginal bacterial flora and other risk factors for vulvovaginal candidiasis. J. Infect. Dis. 2009; 199(12): 1883-90.
25. Погосян Ш.М., Межевитинова Е.А., Абакарова П.Р., Донников А.Е., Муравьева В.В. Профиль экспрессии генов иммунного ответа во влагалище женщин при комплексной терапии рецидивирующего вульвовагинального кандидоза. Гинекология. 2017; 19(3): 49-54. [Pogosyan Sh.M., Mezhevitinova E.A., Abakarova P.R., Donnikov A.E., Muraveva V.V. The profile of the expression of the immune response genes in the vagina of women in the complex therapy of recurrent vulvovaginal candidiasis. Ginekologiya. 2017; 19(3): 49-54. (in Russian)]
26. Liu M.B., Xu S.R., He Y., Deng G.H., Sheng H.F., Huang X.M. et al. Diverse vaginal microbiomes in reproductive-age women with vulvovaginal candidiasis. PLoS One. 2013; 8(11): e79812.
27. Atashili J., Poole C., Ndumbe P.M., Adimora A.A., Smith J.S. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS. 2008; 22(12): 1493-501.
28. Aldunate M., Srbinovski D., Hearps A.C., Latham C.F., Ramsland P.A., Gugasyan R. et al. Antimicrobial and immune modulatory effects of lactic acid and short chain fatty acids produced by vaginal microbiota associated with eubiosis and bacterial vaginosis. Front. Physiol. 2015; 6: 164.
29. Cheng S.C., van de Veerdonk F., Smeekens S., Joosten L.A., van der Meer J.W., Kullberg B.J., Netea M.G. Candida albicans dampens host defense by downregulation IL-17 production. J. Immunol. 2010; 185(4): 2450-7.
30. van de Veerdonk F.L., Marijnissen R.J., Kullberg B.J., Koenen H.J., Cheng S.C., Joosten I. et al. The macrophage mannose receptor induces IL-17 in response to Candida albicans. Cell Host Microbe. 2009; 5(4): 329-40.
31. Zipfel P.F., Skerka C., Kupka D., Luo S. Immune escape of the human facultative pathogenic yeast Candida albicans. The many faces of the Candida Pra1 protein. Int. J. Med. Microbiol. 2011; 301(5): 423-30.
32. Martinez R.C., Franceschini S.A., Patta M.C., Quintana S.M., Candido R.C., Ferreira J.C. et al. Improved treatment of vulvovaginal candidiasis fluconazole plus probiotic Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14. Lett. Appl. Microbiol. 2009; 48(3): 269-74.
33. Oduyebo O.O., Anorlu R.I., Ogunsola F.T. The effects of antimicrobial therapy on bacterial vaginosis in non-pregnant women. Cochrane Database Syst. Rev. 2009; (3): CD006055.
34. De Backer E., Dubreuil L., Brauman M., Acar J., Vaneechoutte M. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin. Microbiol. Infect. 2010; 16(5): 470-2.
35. Donders G.G., Mertens I., Bellen G., Pelckmans S. Selfelimination of risk factors for recurrent vaginal candidosis. Mycoses. 2009; 54(1): 39-45.
36. Pappas P.G., Kauffman C.A., Andes D.R., Clancy C.J., Marr K.A., Ostrosky-Zeichner L. et al. Clinical practice guideline for the management of candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin. Infect. Dis. 2016; 62(4): e1-50.
37. Spence D. Candidiasis (vulvovaginal). BMJ Clin. Evid. 2010; 2010: pii: 0815.
38. Ventolini G. Progresses in vaginal microflora physiology and implications for bacterial vaginosis and candidiasis. Womens Health (Lond.) 2016; 12(3): 283-91.
39. Schuster M.G., Edwards J.E. Jr., Sobel J.D., Chaim W., Wiesenfeld H.C. Empirical fluconazole versus placebo for intensive care unit patients: a randomized trial. Ann. Intern. Med. 2008; 149: 83-90.
40. Мирзабалаева А.К., Климко Н.Н. Диагностика и лечение кандидоза половых органов у женщин, девочек и подростков. Учебное пособие. СПб.; 2009. [Mirzabalayeva A.K., Klimko N.N. Diagnosis and treatment of genital candidiasis in women, girls and adolescents. Tutorial. St. Petersburg; 2009. (in Russian)]
41. Marchaim D., Lemanek L., Bheemreddy S., Kaye K.S., Sobel J.D. Fluconazole-resistant Candida albicans vulvovaginitis. Obstet. Gynecol. 2012;120(6): 1407-14.
42. Веселов А.В., Климко Н.Н., Кречикова О.И., Клясова Г.А., Агапова Е.Д., Мултых И.Г., Розанова С.М., Крайнова Л.Е., Дмитриева Н.В., Козлов Р.С. In vitro флуконазола и вориконазола в отношении более 10 000 штаммов дрожжей: результаты 5-летнего проспективного исследования ARTEMIS Disk в России. Микробиология и антимикробная химиотерапия. 2008; 10(4): 345-54. [Veselov A.V., Klimko N.N., Krechikova O.I., Klyasova G.A., Agapova E.D., Multykh I.G., Rozanova S.M., Krainova L.E., Dmitrieva N.V., Kozlov R.S. In vitro fluconazole and voriconazole for more than 10,000 yeast strains: the results of a 5-year prospective study by ARTEMIS Disk in Russia. Mikrobiologiya i antimikrobnaya himioterapiya. 2008; 10 (4): 345-54. (in Russian)]
43. Долго-Сабурова Ю.В., Мирзабалаева А.К., Климко Н.Н. О проблеме резистентности возбудителей рецидивирующего вульвовагинального кандидоза. Гинекология. 2014; 16(1): 110-4. [Dolgo-Saburova Yu.V., Mirzabalayeva A.K., Klimko N.N. On the problem of resistance of pathogens of recurrent vulvovaginal candidiasis. Ginekologiya. 2014; 16 (1): 110-4. (in Russian)]
44. Mendling W., Brasch J.; German Society for Gynecology and Obstetrics. Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics. Mycoses. 2012; 55(Suppl. 3): 1-13.
Received 12.04.2018
Accepted 28.04.2018
About the Authors
Irina Vsevolodovna Kuznetsova, MD, Professor of the Department of Obstetrics and Gynecology, I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia. 119146, Russia, Moscow, Bolshaya Pirogovskaya str. 19 bld. 1Raisa Alekseevna Chilova, MD, Professor of the Department of Obste
For citations: Kuznetsova I.V., Chilova R.A. Bacterial vaginosis and vulvovaginal candidiasis. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (5): 143-9. (in Russian)
https://dx.doi.org/10.18565/aig.2018.5.143-149
Similar Articles
